PE20131046A1 - Derivados aminolactama como agentes anti-inflamatorios - Google Patents

Derivados aminolactama como agentes anti-inflamatorios

Info

Publication number
PE20131046A1
PE20131046A1 PE2012002286A PE2012002286A PE20131046A1 PE 20131046 A1 PE20131046 A1 PE 20131046A1 PE 2012002286 A PE2012002286 A PE 2012002286A PE 2012002286 A PE2012002286 A PE 2012002286A PE 20131046 A1 PE20131046 A1 PE 20131046A1
Authority
PE
Peru
Prior art keywords
inflammatory agents
ona
aminolactam
tetrahydropyridin
integer
Prior art date
Application number
PE2012002286A
Other languages
English (en)
Inventor
David John Grainger
David John Fox
Original Assignee
Boehringer Ingelheim Int
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471347&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131046(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int, Cambridge Entpr Ltd filed Critical Boehringer Ingelheim Int
Publication of PE20131046A1 publication Critical patent/PE20131046A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74Oxygen atoms
    • C07D211/76Oxygen atoms attached in position 2 or 6
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

REFERIDA A UN DERIVADO DE 3-AMINOLACTAMA DE FORMULA (I), DONDE n ES UN ENTERO DE 1 A 4; k ES UN ENTERO DE 1 A 5; X ES UN GRUPO ALQUILO, HALOALQUILO, HIDROXIALQUILO, ENTRE OTROS. SON COMPUESTOS FAVORITOS: (S)-3-(4'-ETILBENZOILAMINO)-AZEPAN-2-ONA, (S)-3-(4'-OCTILBENZOILAMINO)-TETRAHIDROPIRIDIN-2-ONA, (S)-3-(4'-HEXILBENZOILAMINO)-TETRAHIDROPIRIDIN-2-ONA, ENTRE OTROS. DICHOS COMPUESTOS TIENEN ACTIVIDAD INHIBIDORA DE QUIMIOQUINAS Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADESINFLAMATORIAS
PE2012002286A 2010-06-08 2011-06-08 Derivados aminolactama como agentes anti-inflamatorios PE20131046A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1009603.0A GB201009603D0 (en) 2010-06-08 2010-06-08 Anti-inflammatory agent

Publications (1)

Publication Number Publication Date
PE20131046A1 true PE20131046A1 (es) 2013-09-23

Family

ID=42471347

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012002288A PE20130772A1 (es) 2010-06-08 2011-06-08 Derivados de sulfonamida de 3-aminolactamas como agentes anti-inflamatorios
PE2012002286A PE20131046A1 (es) 2010-06-08 2011-06-08 Derivados aminolactama como agentes anti-inflamatorios

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2012002288A PE20130772A1 (es) 2010-06-08 2011-06-08 Derivados de sulfonamida de 3-aminolactamas como agentes anti-inflamatorios

Country Status (20)

Country Link
US (2) US20130203734A1 (es)
EP (2) EP2580196A1 (es)
JP (2) JP2013528201A (es)
KR (2) KR20130115082A (es)
CN (2) CN103080090A (es)
AP (2) AP2012006560A0 (es)
AU (1) AU2011263531A1 (es)
BR (2) BR112012030816A2 (es)
CA (2) CA2798213A1 (es)
CL (1) CL2012003460A1 (es)
CO (2) CO6670553A2 (es)
GB (1) GB201009603D0 (es)
IL (2) IL222798A0 (es)
MA (2) MA34369B1 (es)
MX (2) MX2012014290A (es)
PE (2) PE20130772A1 (es)
SG (2) SG185130A1 (es)
TN (2) TN2012000521A1 (es)
WO (2) WO2011154695A1 (es)
ZA (2) ZA201208367B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA039391B1 (ru) * 2017-09-07 2022-01-21 Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3054738B2 (ja) * 1988-07-22 2000-06-19 武田薬品工業株式会社 チアゾロ[5,4―b]アゼピン誘導体
JPH03206042A (ja) 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
IT1247698B (it) 1990-06-21 1994-12-30 Sigma Tau Ind Farmaceuti 1-alchil-3-(acilammino)-e-caprolattami quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
DE4117507A1 (de) * 1991-05-24 1992-11-26 Schering Ag Verfahren zur herstellung von n(pfeil hoch)6(pfeil hoch)-substituierten lysin-derivaten
JP3206042B2 (ja) 1991-10-31 2001-09-04 ミノルタ株式会社 新規トリアミノ化合物を用いた電荷輸送材料、このトリアミノ化合物を含有する感光体およびエレクトロルミネセンス素子
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
EP1141011A2 (en) 1999-01-12 2001-10-10 Neorx Corporation Compounds and methods to inhibit or augment an inflammatory response
AU2003269850A1 (en) 2002-10-08 2004-05-04 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
ZA200507806B (en) * 2003-03-24 2007-03-28 Actimis Pharmaceuticals Inc 2-phenoxy- and 2-enysulfomamide derivatives with CCR3 antagonistic acitivity for the treatment of asthma and other inflammatory or immunolgical disorders
WO2005042489A1 (en) * 2003-10-29 2005-05-12 Elan Pharmaceuticals, Inc. N-substituted benzene sulfonamides
EP1691814B9 (en) * 2003-12-01 2013-02-20 Cambridge Enterprise Limited Anti-inflammatory agents
RU2378258C2 (ru) * 2004-07-13 2010-01-10 Ф. Хоффманн-Ля Рош Аг Производные сульфонамида
GB2418425B (en) * 2004-08-11 2008-09-03 Univ Cambridge Tech Anti-inflammatory agents
GB2418426A (en) 2004-08-18 2006-03-29 Univ Cambridge Tech Alpha-(acylamino)-bicyclolactam derivatives for treatment of inflammatory disorders
GB2423085C (en) 2005-02-11 2011-11-09 Cambridge Entpr Ltd Ligands for G-protein coupled receptors
GB0512238D0 (en) * 2005-06-15 2005-07-27 Univ Cambridge Tech Anti-inflammatory agents
US7803794B2 (en) * 2005-06-15 2010-09-28 Cambridge Enterprise Limited Anti-inflammatory agents
JP4885958B2 (ja) 2005-08-12 2012-02-29 エフ.ホフマン−ラ ロシュ アーゲー フルオロ置換2−オキソアゼパン誘導体
EP1928236B1 (en) 2005-09-27 2011-11-23 Irm Llc Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
WO2009017620A1 (en) 2007-07-26 2009-02-05 Ipsen Pharma S.A.S. Chemokine analogs
GB2452696B (en) 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions

Also Published As

Publication number Publication date
GB201009603D0 (en) 2010-07-21
CA2798213A1 (en) 2011-12-15
CO6670553A2 (es) 2013-05-15
AP2012006560A0 (en) 2012-12-31
BR112012031136A2 (pt) 2017-08-08
JP2013528201A (ja) 2013-07-08
TN2012000521A1 (en) 2014-04-01
CN103080090A (zh) 2013-05-01
JP2013531647A (ja) 2013-08-08
PE20130772A1 (es) 2013-07-03
KR20130115082A (ko) 2013-10-21
WO2011154696A1 (en) 2011-12-15
EP2580196A1 (en) 2013-04-17
MX2012014290A (es) 2013-05-01
EP2580197A1 (en) 2013-04-17
CO6670569A2 (es) 2013-05-15
US20130203734A1 (en) 2013-08-08
IL222798A0 (en) 2012-12-31
MA34370B1 (fr) 2013-07-03
MA34369B1 (fr) 2013-07-03
CN103119021A (zh) 2013-05-22
WO2011154695A1 (en) 2011-12-15
SG185129A1 (en) 2012-12-28
KR20130086952A (ko) 2013-08-05
CA2798129A1 (en) 2011-12-15
ZA201208367B (en) 2013-10-30
BR112012030816A2 (pt) 2016-11-01
AU2011263531A1 (en) 2012-11-22
TN2012000525A1 (en) 2014-04-01
US20130172318A1 (en) 2013-07-04
SG185130A1 (en) 2012-12-28
ZA201208406B (en) 2013-07-31
AP2012006559A0 (en) 2012-12-31
MX2012014291A (es) 2013-05-01
CL2012003460A1 (es) 2013-08-16
IL222866A0 (en) 2012-12-31

Similar Documents

Publication Publication Date Title
CR20110620A (es) Derivados de n-(hetero)aril-pirrolidina de pirazo-4-il-pirrolo[2,3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como ihnibidores de la quinasa janus
EA201390198A1 (ru) Гетероциклическое соединение
UY32543A (es) Análogos de isoxazol-3(2h)-ona como agentes terapéuticos
MX336381B (es) Boronatos como inhibidores de arginasa.
EA201290460A1 (ru) Производные азола, способы их получения, промежуточные продукты, средства для сельского хозяйства и садоводства
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
NZ723198A (en) Anthelmintic compounds and compositions and methods of using thereof
CR20120190A (es) INHIBIDORES DE N1-PIRAZOLOESPIROCETONA ACETIL-CoA CARBOXILASA
MA33939B1 (fr) 5-alcynyl-pyrimidines
MA32811B1 (fr) Nouveaux composés
MX338114B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
CO6680667A2 (es) Derivados ester de ácido borónico cíclico y sus usos terapéuticos
UA112061C2 (uk) Активуючі ampk гетероциклічні сполуки і способи їх використання
MX2012001787A (es) Carboxamidas como plaguicidas.
UA108743C2 (uk) Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази
CR10771A (es) Derivados de 2-[1-fenil-5-hidroxi-4alfa-metil-hexahidrociclopenta [f] indazol-5-il]etil fenilo como ligandos del receptor glucocorticoide
ECSP067120A (es) 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas
EA201071040A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40
UY33694A (es) ?inhibidores de n1/n2-lactama acetil-coa carboxilasa?.
EA201100750A1 (ru) Замещенные диоксопиперидинилфталимидные производные
UY32859A (es) Compuestos y composiciones como inhibidores de cinasa de proteina
AR089781A1 (es) Fluorometil-5,6-dihidro-4h-[1,3]oxazinas
UY35182A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[ 3,4-d][1,3]TIAZIN-2-AMINA? .
CO2017000980A2 (es) Compuestos derivados de imidazo[1,2-b]piridazin-2-carboxamida e imidazo[1,2- b]piridazin-2-ilmetanona activos como inhibidores selectivos de la fosfodiesterasa 4a (pde4a)
MX2013012652A (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparacion y su uso como antagonistas p2y12.

Legal Events

Date Code Title Description
FD Application declared void or lapsed